

## Esbriet<sup>®</sup> (pirfenidone) – First-time generic

- On May 4, 2022, Sandoz launched an [AB-rated](#) generic version of Genentech's [Esbriet \(pirfenidone\)](#) tablets.
  - Patent litigation is ongoing concerning this generic launch.
  - In addition, [Accord](#), [Amneal](#), and [Teva](#) received FDA approval of AB-rated generic versions of Esbriet tablets on January 25, 2022, March 25, 2022, and January 25, 2022, respectively. Launch of these generics are pending.
- Esbriet is approved for the treatment of idiopathic pulmonary fibrosis (IPF).
- Esbriet is also available as a brand capsule indicated for IPF.
  - Accord received FDA approval of an [AB-rated](#) generic version of Esbriet capsule on January 20, 2022, and launch is pending.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.